SHU atypique: RARE à l’écoute Podcasts
Si vous désirez vous informer et aller plus loin dans la connaissance de cette maladie rare, nous vous invitons à lire…
aHUS are we there yet?
Last summer, aHUS alliance’s Twitter Account featured the plight of a patient who, after a week in hospital, had been found…
COVID and aHUS at the end of 2021
As the year ends we are still living with COVID. It seems like it is never ending. And it is and…
Living with aHUS- what would you say?
If asked by health policy decision makers, and with a 500 words limit, how would you answer the question "how does…
Good complement goes aHUS bad
OK, so HUS is caused by e.coli toxins and aHUS results from Complement dysregulation. Both are thrombotic microangiopathies. HUS is…
Ravulizumab -Superwoman juice?
The portrayal of rare diseases in the media can be both positive and detrimental. It can be sensational and political. It…
Bergamo aHUS symposium gets the go ahead
In the weeks leading up to aHUS awareness day an announcement was made which did not get the attention it perhaps…
Ravulizumab is not quite eculizumab
Ravulizumab is becoming a treatment of choice for aHUS in countries where access is funded. Though eculizumab will still have a…
Ecu to ravu transfer UPDATE
Update news on switching process. aHUS alliance Global Action were not aware of a prior step in the switching process to…
- Go to the previous page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- …
- 27
- Go to the next page